Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Post by Youhillmanon Nov 19, 2020 2:19am
943 Views
Post# 31928881

AdvisorShares increases CRDL ownership by 17.91%

AdvisorShares increases CRDL ownership by 17.91%

FYI....AdvisorShares has an ETF that includes CRDL, they have held this position for over a year, last week they increased their number of shares by 17.91%, so obviously they continue to like the CRDL story!

Share weakness right now is due to the market conditions, it's needing a catalyst to generate further share price strength. 

In December look for phase one approval by the FDA for AM, hopefully we might also see a NASDAQ listing. 

If one or both occur they will be a very positive catalyst.


AdvisorShares Investments LLC reports 17.91% increase in ownership of CRDL / Cardiol Therapeutics Inc

November 12, 2020 - AdvisorShares Investments LLC has filed a 13F-HR form disclosing ownership of 287,106 shares of Cardiol Therapeutics Inc (CA:CRDL) with total holdings valued at $876,000 USD as of September 30, 2020. AdvisorShares Investments LLC had filed a previous 13F-HR on July 14, 2020 disclosing 243,504 shares of Cardiol Therapeutics Inc at a value of $577,000 USD. This represents a change in shares of 17.91 percent and a change in value of 51.82 percent during the quarter.

<< Previous
Bullboard Posts
Next >>